Abbott India Ltd. News and Updates

Name: Latest research reports of Abbott India Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Abbott India Ltd.
Rating: 5
Author: ICICI Securities Limited

Keep track of all breaking news on Abbott India Ltd. from all sources in a single place.

Abbott India Ltd.

06 Feb 2025

30720.55

0.50%

Abbott India gains 10% in 2 days after posting healthy Q3 show; Details

Business Standard

The company's Q3 profit increased 16 per cent year-on-year (Y-o-Y) to Rs 360.78 crore as compared to Rs 310.98 crore

Number of FII/FPI investors decreased from 85 to 78 in Dec 2024 qtr

Abbott India Ltd.

06 Feb 2025

30720.55

0.50%

Stellar quarter; growth pace accelerating

Buy: Abbott India Ltd.

Target

ICICI Securities Limited

Abbott India’s (Abbott) impressive revenue growth of 12.3% YoY in Q3FY25 was ahead of our expectation. As per IQVIA, this may be driven by key brands of Novo Nordisk like Rybelsus and Ryzodeg and owned brands like Duphalac, Udiliv and Thyronorm.

Abbott India Ltd. is trading above all available SMAs

Abbott India Ltd.

06 Feb 2025

30720.55

0.50%

Result Update:Abbott India

Buy: Abbott India Ltd.

Target

Axis Direct

We maintain a BUY rating on the stock

Abbott India Ltd. has an average target of 31900.00 from 3 brokers.

Abbott India Ltd.

19 Dec 2024

30720.55

0.50%

Abbott India share rises 3% as JPMorgan ups target to Rs 31,500; details

Business Standard

The surge in Abbott India share price followed reports that JPMorgan, a New York-based financial services firm, raised its target price to Rs 31,500, up from Rs 30,000, signaling an upside of 12%

Abbott India Ltd. is trading above all available SMAs

Abbott India Ltd.

08 Nov 2024

30720.55

0.50%

Result Update:Abbott India

Buy: Abbott India Ltd.

Axis Direct

we maintain a BUY rating on the stock. We have set a target price of Rs 31,420/share, which implies an upside potential of 12% from the CMP.

Number of FII/FPI investors decreased from 85 to 78 in Dec 2024 qtr

Abbott India Ltd.

07 Nov 2024

30720.55

0.50%

Abbott India Q2 Results: Profit Rises 15%, Beating Estimates

NDTV Profit

Abott India reported a net profit of Rs 359 crore, compared with the consensus estimate of Rs 237 crore.

Abbott India Ltd. is trading above all available SMAs

Abbott India Ltd.

26 Oct 2024

30720.55

0.50%

Pick of the Week:28 October 2024

Buy: Abbott India Ltd.

Target

Axis Direct

We recommend a BUY with a target price of Rs 31,420/share (46.5x P/E for FY26E), implying an upside of 10% from the CMP.

Number of FII/FPI investors decreased from 85 to 78 in Dec 2024 qtr

Abbott India Ltd.

28 Aug 2024

30720.55

0.50%

Abbott India recalls Pentids antibiotic batches over packaging issues

Business Standard

Pentids are widely prescribed for treating bacterial infections of the respiratory tract, throat, lungs, nose, skin, and sexually transmitted diseases like syphilis

Abbott India Ltd. is trading above all available SMAs

Abbott India Ltd.

08 Aug 2024

30720.55

0.50%

Here's why Abbott India stock price surged 5% on August 8; details here

Business Standard

The uptick in the pharma company's stock price came after it posted a healthy set of numbers in the June quarter of financial year 2025 (Q1FY25).

Abbott India Ltd. has an average target of 31900.00 from 3 brokers.

Abbott India Q1 results: PAT rises 13% to Rs 328 cr, income at Rs 1,625 cr

Business Standard | 07 Aug 2024

Abbott India Ltd.

08 Aug 2024

30720.55

0.50%

Healthy earnings: growth momentum to continue

Buy: Abbott India Ltd.

Target

Sharekhan

Earnings were in line with our estimates, where sales grew by 5% y-o-y to Rs 1,557 crore (1.6% below our estimates), EBITDA grew by 10% y-o-y to Rs 3,910 crore.